Pathogenese, Klinik und aktuelle Therapie der Rosazea
| Autor: | Martin Schaller, C. E. Gonser, L. I. Gonser |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
0301 basic medicine
Doxycycline medicine.medical_specialty Allergy biology business.industry Brimonidine Dermatology Ocular rosacea medicine.disease biology.organism_classification 030207 dermatology & venereal diseases 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Ivermectin medicine.anatomical_structure Rosacea medicine business Nose Demodex medicine.drug |
| Zdroj: | Der Hautarzt. 67:69-84 |
| ISSN: | 1432-1173 0017-8470 |
| Popis: | Rosacea is a common chronic inflammatory disease, especially in patients with fair skin and positive family history. Typical locations are forehead, nose, cheeks and chin; the periorbital region is usually not involved. Clinical features can be very heterogeneous. Besides different subtypes (erythematotelangiectatic rosacea, papulopustular rosacea, phymatous rosacea), which often overlap, various special forms of rosacea exist. Up to 60% of patients with cutaneous rosacea suffer from ocular rosacea. In Germany, brimonidine, metronidazol, azelaic acid, and ivermectin are approved for topical therapy of rosacea; for systemic therapy, doxycycline at a subantimicrobial dose (40 mg/day) is the only approved substance. In case of resistance to this therapy, contraindications or side effects, various alternative therapies are available, however off-label. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink